Approaches to the emerging business of cannabis products seem to change on a daily basis: Legal? Illegal? Beneficial? Harmful? This webinar will provide an overview of the current state of cannabis regulation. We will first discuss scientific definitions of various cannabis-derived substances, including CBD, THC, and hemp, and the pharmacology of how these substances can affect the body. Our experts will then provide updates to various federal agencies’ regulation of cannabis products, as well as implications for companies operating in states that have legalized cannabis for medical and/or recreational purposes. Finally, we will provide an update on international governing bodies’ approaches to cannabis regulation.

Get Access

  • +$100 for nonmembers

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.


William Garvin, Shareholder, Buchanan Ingersoll & Rooney PC
Aidan Hampson, Special Content Expert Cannabis, NIDA
Jonathan Havens, Partner, Chair of Food & Beverage Practice, Co-Chair of Cannabis Law Practice, Saul Ewing Arnstein & Lehr LLP
Larry Houck, Director, Hyman, Phelps & McNamara, PC
Moderated by Bridget Dooling, Research Professor, George Washington University

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.


On-demand content can be played back on most devices.


CLE credit is not currently available for pre-recorded sessions.